Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Virus Reduction of Human Plasma-Derived Biological Medicines

Shahnaz Nazari 1 , Mohammad Ali Jalili 2 , Majid Shahabi 3 , Mohammad Fallah Tafti 3 , Saleh Nasiri 3 , Mohammad Mouradi 3 and Kamran Mousavi Hosseini 3 , *
Authors Information
1 Department of Environmental Engineering, Islamic Azad University, Central Tehran Branch, Tehran, Iran
2 Department of Biochemistry, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
3 Department of Biotechnology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 2017, 12 (2); e13943
  • Published Online: February 28, 2017
  • Article Type: Review Article
  • Received: August 15, 2016
  • Revised: November 29, 2016
  • Accepted: December 26, 2016
  • DOI: 10.5812/jjnpp.13943

To Cite: Nazari S, Jalili M A, Shahabi M, Fallah Tafti M, Nasiri S, et al. Virus Reduction of Human Plasma-Derived Biological Medicines, Jundishapur J Nat Pharm Prod. 2017 ; 12(2):e13943. doi: 10.5812/jjnpp.13943.

Abstract
Copyright © 2017, Jundishapur Journal of Natural Pharmaceutical Products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnote
References
  • 1. Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, et al. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion. 2016; 56(2): 383-91[DOI][PubMed]
  • 2. Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion. 2012; 52 Suppl 1: 9S-19S[DOI][PubMed]
  • 3. Schneider T. [Therapeutic plasmas]. Transfus Clin Biol. 2012; 19(4-5): 148-9[DOI][PubMed]
  • 4. Mousavi Hosseini K, Nasiri S. Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography. Med J Islam Repub Iran. 2015; 29: 170[PubMed]
  • 5. Mousavi Hosseini K, Nikougoftar Zarif M. Preparation of plasminogen by affinity chromatography. Iran J Blood Cancer. 2014; 6(4): 163-7
  • 6. Mousavi Hosseini K, Pourmokhtar M, Dinar Vand R, Rezvan H, Jalili MA. Preparation of enriched immunoglobulin M and immunoglobulin A from human plasma. Med J Islam Repub Iran. 2004; 17(4): 315-8
  • 7. Yari F, Mousavi Hosseini K. Simultaneous purification and polymerization method for bovine serum albumin preparation. Ital J Biochem. 2007; 56(2): 163-5[PubMed]
  • 8. Lozano M, Cid J. Pathogen inactivation: coming of age. Curr Opin Hematol. 2013; 20(6): 540-5[DOI][PubMed]
  • 9. Mousavi Hosseini K, Pourmokhtar M, Habibi Roudkenar M, Shahabi M. Human plasma derived drugs separation by fractionation of plasmawith polyethylene glycol. Iran J Biotechnol. 2014; 12(3): 82-5[DOI]
  • 10. Clement S. [Techniques of preparation and indications of labile blood products]. Transfus Clin Biol. 2011; 18(2): 250-61[DOI][PubMed]
  • 11. Mousavi Hosseini MK, Pourmokhtar M, Jalili MA, Nasiri S. Immunoglobulin A preparation from human pooled plasma using plasma fractionation and ion exchange chromatography. Iran J Blood Cancer. 2014; 6(2): 75-9
  • 12. Morgenthaler JJ. New developments in plasma fractionation and virus inactivation. Vox Sang. 2000; 78 Suppl 2: 217-21[PubMed]
  • 13. Nasiri S, Mousavi Hosseini K. Effects of centrifugation speed on platelet aggregation activity [In Persian]. Koomesh. 2014; 15(2): 250-4
  • 14. Roberts PL. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors. Biologicals. 2014; 42(4): 184-90[DOI][PubMed]
  • 15. Rezvan H, Motallebi Z, Jalili MA, Mousavi Hosseini K, Pourfathollah AA. Safety of blood and plasma derivatives: pathogen reducing technologies. Med J Islam Repub Iran. 2006; 20(2): 86-92
  • 16. Nasiri S, Mousavi Hosseini MK. Infusible platelet membrane versus conventional platelet concentrate: benefits and disadvantages. Iran J Blood Cancer. 2014; 6(2): 87-93
  • 17. Sauvage V, Eloit M. Viral metagenomics and blood safety. Transfus Clin Biol. 2016; 23(1): 28-38[DOI][PubMed]
  • 18. Klamroth R, Groner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion. 2014; 54(5): 1406-17[DOI][PubMed]
  • 19. Mousavi Hosseini K, Nasiri S, Heidari M. Using ethanol and low temperature in separation of albumin from human plasma. J Zanjan Univ Med Sci Health Serv. 2013; 21(85): 65-7
  • 20. Mousavi Hosseini K, Heidari M, Yari F. The preparation of albumin as a biological drug from human plasma by fiber filtration [In Persian]. Tehran Univ Med J. 2011; 69(5): 283-8
  • 21. Belousova IM, Kislyakov IM, Muraviova TD, Starodubtsev AM, Kris'ko TK, Selivanov EA, et al. Photodynamic inactivation of enveloped virus in protein plasma preparations by solid-phase fullerene-based photosensitizer. Photodiagnosis Photodyn Ther. 2014; 11(2): 165-70[DOI][PubMed]
  • 22. Mahmoodian Shooshtari M, Mousavi Hosseini K. Evaluation of the plasma quality after filtration. Daru. 2010; 18(2): 114-7[PubMed]
  • 23. Mousavi Hosseini K, Sharifi Z. Quality assurance and Good Manufacturing Practice in respect of plasma fractionation. I J Blood Cancer. 2011; 3(3): 139-46
  • 24. Rubsamen-Waigmann H. [Virus inactivation of plasma products. Practical methods and their safety]. Dtsch Med Wochenschr. 1994; 119(10): 345-8[DOI][PubMed]
  • 25. Wigginton KR, Pecson BM, Sigstam T, Bosshard F, Kohn T. Virus inactivation mechanisms: impact of disinfectants on virus function and structural integrity. Environ Sci Technol. 2012; 46(21): 12069-78[DOI][PubMed]
  • 26. Jilma-Stohlawetz P, Kursten FW, Horvath M, Leitner G, List J, Marcek J, et al. Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion. 2013; 53(9): 1906-17[DOI][PubMed]
  • 27. Mousavi Hosseini K, Jalili MA. Synthesis of vitamin e novel analogues as anti-cancer compounds. Jundishapur J Nat Pharm Prod. 2016; 11(1)[DOI]
  • 28. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion. 2003; 43(8): 1023-8[DOI][PubMed]
  • 29. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 2000; 14(2): 94-110[DOI][PubMed]
  • 30. Sheffield WP, Bhakta V, Talbot K, Pryzdial EL, Jenkins C. Quality of frozen transfusable plasma prepared from whole blood donations in Canada: an update. Transfus Apher Sci. 2013; 49(3): 440-6[DOI][PubMed]
  • 31. Stuhler A, Blumel J. [Viral safety of biological medicinal products]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014; 57(10): 1198-202[DOI][PubMed]
  • 32. Wieser A, Berting A, Medek C, Poelsler G, Kreil TR, Global Pathogen Safety B. Virus Filtration and Flow Variation: An Approach To Evaluate Any Potential Impact on Virus Retention. PDA J Pharm Sci Technol. 2016; 70(4): 325-31[DOI][PubMed]
  • 33. Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N, et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang. 2004; 86(4): 225-9[DOI][PubMed]
  • 34. Koenderman AH, ter Hart HG, Prins-de Nijs IM, Bloem J, Stoffers S, Kempers A, et al. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step. Biologicals. 2012; 40(6): 473-81[DOI][PubMed]
  • 35. Furuya K, Murai K, Yokoyama T, Maeno H, Takeda Y, Murozuka T, et al. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process. Vox Sang. 2006; 91(2): 119-25[DOI][PubMed]
  • 36. Kashef N, Behzadian-Nejad Q, Najar-Peerayen S, Mousavi-Hosseini K, Moazeni M, Rezvan H, et al. Preliminary investigation on the isolation of alginate produced by mucoid Pseudomonas aeruginosa. Ann Microbiol. 2005; 55(4): 279-82
  • 37. Yunoki M, Yamamoto S, Tanaka H, Nishigaki H, Tanaka Y, Nishida A, et al. Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters. Vox Sang. 2008; 95(2): 94-100[DOI][PubMed]
  • 38. Caballero S, Diez JM, Belda FJ, Otegui M, Herring S, Roth NJ, et al. Robustness of nanofiltration for increasing the viral safety margin of biological products. Biologicals. 2014; 42(2): 79-85[DOI][PubMed]
  • 39. Cardone F, Simoneau S, Arzel A, Puopolo M, Berardi VA, Abdel-Haq H, et al. Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" albumin solutions. Transfusion. 2012; 52(5): 953-62[DOI][PubMed]
  • 40. Menconi MC, Maggi F, Zakrzewska K, Salotti V, Giovacchini P, Farina C, et al. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products. Transfus Med. 2009; 19(4): 213-7[DOI][PubMed]
  • 41. Madani TA, Abuelzein el TM, Azhar EI, Al-Bar HM. Thermal inactivation of Alkhumra hemorrhagic fever virus. Arch Virol. 2014; 159(10): 2687-91[DOI][PubMed]
  • 42. Hewitt J, Greening GE. Effect of heat treatment on hepatitis A virus and norovirus in New Zealand greenshell mussels (Perna canaliculus) by quantitative real-time reverse transcription PCR and cell culture. J Food Prot. 2006; 69(9): 2217-23[DOI][PubMed]
  • 43. Mousavi Hosseini K, Rezvan H, Motalleb Z, Chabokpey S, Mirbod V. Study of the heat-treated human albumin stabilization by caprylate and acetyltryptophanate. Iran Biomed J. 2002; 6(4): 135-40
  • 44. Lin JJ, Meyer JD, Carpenter JF, Manning MC. Aggregation of human serum albumin during a thermal viral inactivation step. Int J Biol Macromol. 2009; 45(2): 91-6[DOI][PubMed]
  • 45. Mousavi Hosseini K, Dinarvand R, Pourmokhtar M, Rezvan H, Jalil MA. Pasteurization of IgM-enriched immunoglobulin. DARU. 2004; 12(1): 40-3
  • 46. Rezvan. H. , Nasiri S, Mousavi Hosseini K. Inactivation of polio-virus type-1 and HSV-1 in human coagulation factor VII concentrate by pasteurization. Arch Iran Med. 2001; 4(1): 10-3
  • 47. Jalili MA, Hosseini KM. New synthesis of aminorhodanin and condensed derivatives. Pak J Pharm Sci. 2009; 22(1): 53-7[PubMed]
  • 48. Knevelman A, de Wit HJ, Potstra P, vd Does JA. Development and small-scale production of a severely heated factor VIII concentrate. Vox Sang. 1994; 66(2): 89-95[DOI][PubMed]
  • 49. Winkelman L, Feldman PA, Evans DR. Severe heat treatment of lyophilised coagulation factors. Curr Stud Hematol Blood Transfus. 1989; (56): 55-69[DOI][PubMed]
  • 50. Kim IS, Choi YW, Kang Y, Sung HM, Shin JS. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. J Microbiol Biotechnol. 2008; 18(5): 997-1003[PubMed]
  • 51. Prikhod'ko GG, Vasilyeva I, Reyes H, Wong S, Brown KE, Jameson T, et al. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion. 2005; 45(6): 1011-9[DOI][PubMed]
  • 52. Huangfu C, Zhao X, Lv M, Jia J, Zhu F, Wang R, et al. Inactivation of viruses during a new manufacturing process of alpha2-macroglobulin from Cohn Fraction IV by dry-heat treatment. Transfusion. 2016; 56(9): 2274-7[DOI][PubMed]
  • 53. Smales CM, Pepper DS, James DC. Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose. Biotechnol Bioeng. 2002; 77(1): 37-48[DOI][PubMed]
  • 54. Jackson RA, Mousavi Hosseini K. Phenol–phenoxyl radical equilibria by electron spin resonance: are radicals derived from tocopherol and analogues exceptionally stabilized? J Chem Soc Chem Commun. 1992; (13): 967-8
  • 55. Blumel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 2002; 42(11): 1473-81[DOI][PubMed]
  • 56. Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F. Inactivation of hepatitis A virus in plasma products by vapor heating. Transfusion. 1997; 37(2): 215-20[DOI][PubMed]
  • 57. Neisser-Svae A, Trawnicek L, Heger A, Mehta T, Triulzi D. Five-day stability of thawed plasma: solvent/detergent-treated plasma comparable with fresh-frozen plasma and plasma frozen within 24 hours. Transfusion. 2016; 56(2): 404-9[DOI][PubMed]
  • 58. Vacante D, Connell-Crowley L. Protocol for Evaluation of Virus Inactivation Using Low-pH Treatment. PDA J Pharm Sci Technol. 2014; 68(1): 90-7[DOI][PubMed]
  • 59. Hsieh YT, Mullin L, Greenhalgh P, Cunningham M, Goodrich E, Shea J, et al. Single-use technology for solvent/detergent virus inactivation of industrial plasma products. Transfusion. 2016; 56(6): 1384-93[DOI][PubMed]
  • 60. Cushing MM, Asmis L, Calabia C, Rand JH, Haas T. Efficacy of solvent/detergent plasma after storage at 2-8 degrees C for 5 days in comparison to other plasma products to improve factor V levels in factor V deficient plasma. Transfus Apher Sci. 2016; 55(1): 114-9[DOI][PubMed]
  • 61. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis. 2015; 39(1): 118-28[DOI][PubMed]
  • 62. Nasiri S, Rezvan H, Mousavi Hosseini K, Roostaei MH. Preparation of highly purified S/D coagulation F VII and F IX concentrate from PPSB. Med J Islam Repub Iran. 2001; 15(2): 103-8
  • 63. Rezvan H, Nasiri S, Mousavi Hosseini K, Golabi M. A study on the application and efficacy of solvent-detergent treatment in the process of purifying F VII from prothrombin complex. Med J Islam Repub Iran. 2002; 16(3): 179-82
  • 64. Chou ML, Burnouf T, Chang SP, Hung TC, Lin CC, Richardson CD, et al. TnBPTriton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. PLoS One. 2015; 10(2)[DOI][PubMed]
  • 65. Nesterova NV, Kurkina OV, Samoilenko VA, Skrynnyk MM. Physico-chemical and biological properties of solvent/detergent treated immunoglobuin G preparations. Mikrobiol Z. 2009; 71(6): 35-42[PubMed]
  • 66. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang. 2006; 91(1): 56-62[DOI][PubMed]
  • 67. Pourmokhtar M, Dinarvand R, Mousavi Hosseini K, Rezvan H, Jalili MA. Solvent-detergent treatment of IgM-enriched immunoglobulin. DARU. 2003; 11(2): 47-51
  • 68. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992; 79(3): 826-31[PubMed]
  • 69. Mazzer AR, Perraud X, Halley J, O'Hara J, Bracewell DG. Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A. 2015; 1415: 83-90[DOI][PubMed]
  • 70. Solano S, Segura A, Leon G, Gutierrez JM, Burnouf T. Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. Biologicals. 2012; 40(2): 129-33[DOI][PubMed]
  • 71. Mueller M, Wan C, Hoi KM, Kim DY, Gan HT, Bardor M, et al. Immunoglobulins M survive low-pH conditions used for virus inactivation and for elution from bioaffinity columns. J Pharm Sci. 2013; 102(3): 1125-32[DOI][PubMed]
  • 72. She YM, Cheng K, Farnsworth A, Li X, Cyr TD. Surface modifications of influenza proteins upon virus inactivation by beta-propiolactone. Proteomics. 2013; 13(23-24): 3537-47[DOI][PubMed]
  • 73. Elikaei A, Sharifi Z, Hosseini SM, Latifi H, Musavi Hosseini MK. Inactivation of model viruses suspended in fresh frozen plasma using novel methylene blue based device. Iran J Microbiol. 2014; 6(1): 41-5[PubMed]
  • 74. Steinmann E, Gravemann U, Friesland M, Doerrbecker J, Muller TH, Pietschmann T, et al. Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products. Transfusion. 2013; 53(5): 1010-8[DOI][PubMed]
  • 75. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med. 2001; 11(1): 31-6[DOI][PubMed]
  • 76. Wagner SJ, Robinette D, Storry J, Chen XY, Shumaker J, Benade L. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion. 1994; 34(6): 521-6[DOI][PubMed]
  • 77. Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest. 1995; 24(1-2): 73-85[DOI][PubMed]
  • 78. Blumel J, Rinckel LA, Lee DC, Roth NJ, Baylis SA. Inactivation and neutralization of parvovirus B19 Genotype 3. Transfusion. 2012; 52(7): 1490-7[DOI][PubMed]
  • 79. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci. 2015; 52(1): 19-34[DOI][PubMed]
  • 80. Devine DV, Schubert P. Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk. Hematol Oncol Clin North Am. 2016; 30(3): 609-17[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments